Clinical trials are a crucial part of the drug development process. However, these trials have historically lacked diversity, with underrepresented populations being less likely to participate. The FDA has issued guidance on diversity in clinical trials, emphasizing the importance of including diverse populations in clinical research studies.
At Stryde, we are committed to partnering with sponsors to increase diversity in clinical trials and help implement the FDA guidance on diversity.
The Importance of Diversity in Clinical Trials
Diversity in clinical trials is essential for ensuring that new treatments and therapies are effective and safe for all patients, regardless of their race, ethnicity, or background. Unfortunately, underrepresented populations, such as racial and ethnic minorities, are often excluded from clinical trials. This lack of diversity can lead to limited understanding of how a treatment works in specific populations, which can ultimately result in health disparities.
According to a study by the FDA, although minorities represent approximately 40% of the US population, they only account for about 10% of clinical trial participants. This lack of diversity in clinical trials is a serious problem that needs to be addressed.
“Ensuring diversity in clinical trials is critical to our mission of improving health outcomes for all patients. It’s essential that we include diverse populations in clinical trials to ensure that treatments are safe and effective for everyone.” says Dr. Bakhtari, our Principal Investigator at Stryde. “
The FDA Guidance on Diversity in Clinical Trials
The FDA defines a diverse population as inclusive of all populations defined by demographic factors such as race, ethnicity, sex, gender identity, age, pregnancy status, locaction etc .
The FDA guidance on diversity in clinical trials emphasizes the importance of including diverse (race and ethnicity) populations in clinical research studies. Sponsors are encouraged to develop diversity plans that outline operational measures that will be implemented to ensure diverse clinical trial participation.
Stryde’s Approach to Diversity in Clinical Trials
At Stryde, we recognize the importance of engaging diverse physicians and community-based practices in clinical research. Our comprehensive approach includes leveraging social media and other digital channels, partnering with community-based organizations, and engaging diverse physicians and community-based practices in clinical research. Our network includes ethnically diverse physicians from community practice, providing sponsors with access to diverse patient populations and the expertise of these physicians.
We also understand the challenges of recruiting and retaining participants from underrepresented populations. That’s why we work closely with physicians and healthcare workers to develop diversity plans and implement strategies to increase participation from underrepresented populations. Our goal is to ensure that all patients have access to safe and effective treatments, regardless of their race, ethnicity, or background.
Conclusion
Diversity in clinical trials is essential for ensuring that study results are generalizable to the entire patient population and developing targeted therapies to address health disparities. The FDA guidance on diversity in clinical trials emphasizes the importance of including diverse populations in clinical research studies.
Stryde is committed to working with sponsors to increase diversity in clinical trials and implementing the FDA guidance on diversity. By partnering with sponsors, community-based organizations, and diverse physicians, we can help to ensure that all patients have access to safe and effective treatments, regardless of their race, ethnicity, or background.
Contact us to learn more about our approach to diversity in clinical trials.